This is an info Alert.
  • Home
  • Product
  • Blog
  • Contact

Discover laboratory and life science products for your research. Search our catalog by product name, keyword or catalog number and find the right solution for your laboratory.

Search thousands of research products

Product information & research resources

Support for your product inquiries

Products
All productsSearch products
Resources
ArticlesFAQs
Company
About usContact us
Legal
Terms & conditionsPrivacy policy

© 2026 Gentaur. All rights reserved.
ProductsArticlesContact
0
  1. Home
  2. Products
  3. m6A Mouse Monoclonal Antibody [A8F2]
1/0

m6A Mouse Monoclonal Antibody [A8F2]

Product ID: 8228308


Gentaur Catalog Number

GTR09940081
Select size

100 µL

$695.11
​
Selected
100 µL

$695.11

1

N6-methyladenosine (m6A) is the most prevalent and abundant post-transcriptional RNA modification on eukaryote mRNA, and its biological functions are mediated by special binding proteins (i.e., methyltransferases, demethylases, and effectors) that recognize this modification. The presence of m6A on transcripts contributes to diverse fundamental cellular functions, such as pre-mRNA splicing, nuclear transport, stability, translation, and microRNA biogenesis, implying an association with numerous human diseases. The linkages between m6A and numerous cancer types have been indicated in reports that include stomach cancer, prostate cancer, breast cancer, pancreatic cancer, kidney cancer, mesothelioma, sarcoma, and leukaemia. The impacts of m6A on cancer cell proliferation might be much more profound with more data emerging. The depletion of METTL3 is known to cause apoptosis of cancer cells and reduce invasiveness of cancer cells, while the activation of ALKBH5 by hypoxia was shown to cause cancer stem cell enrichment. m6A has also been indicated in the regulation of energy homeostasis and obesity, as FTO is a key regulatory gene for energy metabolism and obesity. SNPs of FTO have been shown to associate with body mass index in human populations and occurrence of obesity and diabetes. The influence of FTO on pre-adipocyte differentiation has been suggested. The connection between m6A and neuronal disorders has also been studied. For instance, neurodegenerative diseases may be affected by m6A as the cognate dopamine signalling was shown to be dependent on FTO and correct m6A methylation on key signalling transcripts. The mutations in HNRNPA2B1, a potential reader of m6A, have been known to cause neurodegeneration. The IGF2BP1–3, a novel class of m6A reader, has oncogenic functions. IGF2BP1–3 knockdown or knockout decreased MYC protein expression, cell proliferation and colony formation in human cancer cell lines. The ZC3H13, a member of the m6A methyltransferase complex, markedly inhibited colorectal cancer cells growth when knocked down.